Phase 2 Lymphoma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People between 18 and 80 years old
- People who have been diagnosed with transformed DLBCL (a type of lymphoma), confirmed by a tissue sample test
- People who are reasonably active and able to care for themselves, as measured by a standard health performance scale (ECOG score of 0–2)
- People who have signed a consent form agreeing to take part
- People whose blood counts, liver, kidneys, and heart are working well enough to meet the trial's safety requirements (the trial site will assess this through blood tests and a heart scan)
Who may not be able to join:
- People with a known allergy or sensitivity to human or mouse-based antibody medicines
- People who have previously had an organ transplant
- People who have received chemotherapy or certain cancer or immune-system treatments within the past 5 years, or who have previously been treated with any anti-CD20 antibody medication
- People with serious ongoing heart or lung conditions, such as advanced heart failure, a heart attack in the past 6 months, unstable heart rhythm problems, unstable chest pain, or a history of obstructive lung disease or bronchospasm
- People who have had major surgery within 4 weeks before joining the trial (routine diagnostic procedures are not included in this)
- People with a known active infection (bacterial, viral, fungal, or other) at the time of joining, or who have had a serious infection within 2 weeks before starting treatment
- People who have previously had radiotherapy to the chest or the area around the heart
- People with active hepatitis B infection (detectable HBV in the blood); people with a past or inactive hepatitis B infection may still be considered, provided they agree to regular monitoring and antiviral treatment as required (confirm with trial site)
- People with hepatitis C who still have detectable hepatitis C virus in the blood; those with a positive hepatitis C antibody test but undetectable virus by PCR test may be considered (confirm with trial site)
- People with active HIV or syphilis infections
- People who are pregnant or breastfeeding
- People the trial doctor considers unsuitable for the study for other reasons
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Yizhen Liu, M.D., Ph.D., Fudan University
Phone: 021-64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
2-year progression-free survival (PFS) assessed by imaging examination
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.